Abstract
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off-label” repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world’s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Personal protective equipment, Food and Drug Administration, electrocardiogram, coronavirus disease 19, Long QT syndrome, SARS-CoV-2severe acute respiratory syndrome coronavirus 2, FDAFood and Drug Administration, PPEpersonal protective equipment, COVID-19coronavirus disease 19, DI-SCDdrug-induced sudden cardiac death, drug-induced sudden cardiac death, DI-TdPdrug-induced torsades de pointes, drug-induced torsades de pointes, ECGelectrocardiogram, LQTSlong QT syndrome, 【초록키워드】 COVID-19, coronavirus disease, therapy, Hydroxychloroquine, risk, drug, arrhythmia, global pandemic, Health, death, disease, Care, QT-interval, help, treat, professional, Postexposure Prophylaxis, mitigate, risk of COVID-19, Prevent, globe, proportion, receive, ventricular, 【제목키워드】 COVID-19, pharmacotherapy, Potential,